Deng Sheng-Qun, Yang Xian, Wei Yong, Chen Jia-Ting, Wang Xiao-Jun, Peng Hong-Juan
Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Medical University, Dongguan 523808, China.
Vaccines (Basel). 2020 Feb 2;8(1):63. doi: 10.3390/vaccines8010063.
Dengue virus (DENV) has become a global health threat with about half of the world's population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D-tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.
登革病毒（DENV）已成为全球健康威胁，全球约一半人口面临感染风险。虽然DENV引起的疾病在首次感染时具有自限性，但抗体依赖增强（ADE）效应会增加二次感染异型病毒时的死亡率。由于目前尚无特效治疗药物，因此迫切需要研发疫苗以预防感染和疾病进展。目前，只有一种减毒活疫苗，即嵌合黄热病17D四价登革疫苗（CYD-TDV），已在一些国家获得临床使用许可，许多候选疫苗仍在研发中。本文综述了减毒活疫苗、灭活病毒疫苗、重组亚单位疫苗、病毒载体疫苗和DNA疫苗这五种疫苗的研究进展、优缺点。
